Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib

BACKGROUND: Sorafenib is approved as a standard therapy for advanced hepatocellular carcinoma (HCC), but its clinical application is limited due to moderate therapeutic efficacy and high incidence of acquired resistance resulted from elevated levels of SDF-1/CXCR4 axis induced by prolonged sorafenib...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Ning, Liu, Weiqun, Li, Bifei, Nie, Huifang, Liu, Jian, Cheng, Yunlong, Wang, Jichuang, Dong, Haiyan, Jia, Lee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6544999/
https://www.ncbi.nlm.nih.gov/pubmed/31151472
http://dx.doi.org/10.1186/s13046-019-1216-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6544999/
https://www.ncbi.nlm.nih.gov/pubmed/31151472
http://dx.doi.org/10.1186/s13046-019-1216-x

Ejemplares similares